Immunovant (IMVT) Expected to Release Earnings on Monday

Immunovant (NASDAQ:IMVT) is anticipated to post its Q2 2027 results before the market opens on Monday, November 9th. Analysts expect Immunovant to announce earnings of ($0.7370) per share and revenue of $7.09 million for the quarter. Interested persons can find conference call details on the company’s upcoming Q2 2027 earnings overview page for the latest details on the call scheduled for Monday, November 9, 2026 at 8:00 AM ET.

Immunovant (NASDAQ:IMVT) last issued its quarterly earnings data on Thursday, August 6th. The company reported ($0.75) earnings per share for the quarter, missing the consensus estimate of ($0.63) by ($0.12). The company had revenue of $7.09 million during the quarter, compared to the consensus estimate of $7.09 million. During the same period last year, the firm earned ($0.71) EPS. On average, analysts expect Immunovant to post ($2.96) EPS for the current fiscal year and ($3.01) EPS for the next fiscal year.

Immunovant Price Performance

NASDAQ:IMVT opened at $29.17 on Monday. The stock has a market capitalization of $6.03 billion, a price-to-earnings ratio of -10.34 and a beta of 0.95. Immunovant has a 52 week low of $21.43 and a 52 week high of $45.42. The stock’s fifty day moving average is $34.56 and its two-hundred day moving average is $32.04.

Analyst Ratings Changes

IMVT has been the topic of several research analyst reports. Cantor Fitzgerald reiterated an “overweight” rating on shares of Immunovant in a research note on Tuesday, August 25th. UBS Group reaffirmed a “buy” rating on shares of Immunovant in a report on Wednesday, September 23rd. JPMorgan Chase & Co. raised their price objective on Immunovant from $47.00 to $50.00 and gave the stock an “overweight” rating in a report on Tuesday, August 4th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Immunovant in a research report on Friday, October 2nd. Finally, HC Wainwright reissued a “buy” rating on shares of Immunovant in a report on Thursday, September 24th. Eight research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $44.00.

Insider Buying and Selling at Immunovant

In other Immunovant news, CEO Eric Venker sold 3,506 shares of the stock in a transaction that occurred on Friday, October 2nd. The stock was sold at an average price of $34.11, for a total transaction of $119,589.66. Following the completion of the sale, the chief executive officer directly owned 257,075 shares of the company’s stock, valued at approximately $8,768,828.25. This trade represents a 1.35% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Tiago Girão sold 6,606 shares of the company’s stock in a transaction on Wednesday, October 28th. The stock was sold at an average price of $28.50, for a total transaction of $188,271.00. Following the transaction, the chief financial officer owned 234,192 shares of the company’s stock, valued at approximately $6,674,472. The trade was a 2.74% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last ninety days, insiders have sold 24,430 shares of company stock valued at $787,852. Corporate insiders own 1.90% of the company’s stock.

Immunovant Company Profile

Immunovant, Inc (NASDAQ: IMVT) is a clinical-stage biopharmaceutical company developing medicines for autoimmune diseases. The company focuses on conditions in which disease-causing immunoglobulin G (IgG) antibodies contribute to tissue damage and other symptoms.

Immunovant’s lead product candidate is batoclimab, also known as IMVT-1401, a fully human monoclonal antibody designed to inhibit the neonatal Fc receptor (FcRn). By reducing the circulation of pathogenic IgG antibodies, batoclimab is being evaluated as a potential treatment for autoimmune disorders, including generalized myasthenia gravis, thyroid eye disease and chronic inflammatory demyelinating polyneuropathy.